IMNM Quote, Financials, Valuation and Earnings

CEL-SCI Corp. has a net margin of -1080.87% compared to Immunome, Inc.'s net margin of --. Immunome, Inc.'s return on equity of -90.08% beat CEL-SCI Corp.'s return on equity of -266.61%.

Immunome, Inc. has a consensus price target of $25.67, signalling upside risk potential of 32.51%. On the other hand CEL-SCI Corp. has an analysts' consensus of $42.50 which suggests that it could grow by 613.09%. Given that CEL-SCI Corp. has higher upside potential than Immunome, Inc., analysts believe CEL-SCI Corp. is more attractive than Immunome, Inc..

Immunome, Inc. has a beta of 2.175, which suggesting that the stock is 117.492% more volatile than S&P 500. In comparison CEL-SCI Corp. has a beta of 0.487, suggesting its less volatile than the S&P 500 by 51.259%.

Immunome, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. CEL-SCI Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Immunome, Inc. pays -- of its earnings as a dividend. CEL-SCI Corp. pays out -- of its earnings as a dividend.

Immunome, Inc. quarterly revenues are --, which are smaller than CEL-SCI Corp. quarterly revenues of --. Immunome, Inc.'s net income of -$57.5M is lower than CEL-SCI Corp.'s net income of -$5.7M. Notably, Immunome, Inc.'s price-to-earnings ratio is -- while CEL-SCI Corp.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Immunome, Inc. is 158.64x versus -- for CEL-SCI Corp.. Usually stocks with elevated PS ratios are considered overvalued.

Precision BioSciences, Inc. has a net margin of -1080.87% compared to Immunome, Inc.'s net margin of -167476.92%. Immunome, Inc.'s return on equity of -90.08% beat Precision BioSciences, Inc.'s return on equity of -188.9%.

Immunome, Inc. has a consensus price target of $25.67, signalling upside risk potential of 32.51%. On the other hand Precision BioSciences, Inc. has an analysts' consensus of $32.50 which suggests that it could grow by 542.29%. Given that Precision BioSciences, Inc. has higher upside potential than Immunome, Inc., analysts believe Precision BioSciences, Inc. is more attractive than Immunome, Inc..

Immunome, Inc. has a beta of 2.175, which suggesting that the stock is 117.492% more volatile than S&P 500. In comparison Precision BioSciences, Inc. has a beta of 1.110, suggesting its more volatile than the S&P 500 by 10.998%.

Immunome, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Precision BioSciences, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Immunome, Inc. pays -- of its earnings as a dividend. Precision BioSciences, Inc. pays out -- of its earnings as a dividend.

Immunome, Inc. quarterly revenues are --, which are smaller than Precision BioSciences, Inc. quarterly revenues of $13K. Immunome, Inc.'s net income of -$57.5M is lower than Precision BioSciences, Inc.'s net income of -$21.8M. Notably, Immunome, Inc.'s price-to-earnings ratio is -- while Precision BioSciences, Inc.'s PE ratio is 3.41x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Immunome, Inc. is 158.64x versus 72.78x for Precision BioSciences, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

IGC Pharma, Inc. has a net margin of -1080.87% compared to Immunome, Inc.'s net margin of -953.4%. Immunome, Inc.'s return on equity of -90.08% beat IGC Pharma, Inc.'s return on equity of -94.42%.

Immunome, Inc. has a consensus price target of $25.67, signalling upside risk potential of 32.51%. On the other hand IGC Pharma, Inc. has an analysts' consensus of $3.75 which suggests that it could grow by 1141.72%. Given that IGC Pharma, Inc. has higher upside potential than Immunome, Inc., analysts believe IGC Pharma, Inc. is more attractive than Immunome, Inc..

Immunome, Inc. has a beta of 2.175, which suggesting that the stock is 117.492% more volatile than S&P 500. In comparison IGC Pharma, Inc. has a beta of 0.242, suggesting its less volatile than the S&P 500 by 75.839%.

Immunome, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. IGC Pharma, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Immunome, Inc. pays -- of its earnings as a dividend. IGC Pharma, Inc. pays out -- of its earnings as a dividend.

Immunome, Inc. quarterly revenues are --, which are smaller than IGC Pharma, Inc. quarterly revenues of $191K. Immunome, Inc.'s net income of -$57.5M is lower than IGC Pharma, Inc.'s net income of -$1.8M. Notably, Immunome, Inc.'s price-to-earnings ratio is -- while IGC Pharma, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Immunome, Inc. is 158.64x versus 22.66x for IGC Pharma, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

NovaBay Pharmaceuticals, Inc. has a net margin of -1080.87% compared to Immunome, Inc.'s net margin of -255.85%. Immunome, Inc.'s return on equity of -90.08% beat NovaBay Pharmaceuticals, Inc.'s return on equity of -306.03%.

Immunome, Inc. has a consensus price target of $25.67, signalling upside risk potential of 32.51%. On the other hand NovaBay Pharmaceuticals, Inc. has an analysts' consensus of $0.85 which suggests that it could fall by -19.81%. Given that Immunome, Inc. has higher upside potential than NovaBay Pharmaceuticals, Inc., analysts believe Immunome, Inc. is more attractive than NovaBay Pharmaceuticals, Inc..

Immunome, Inc. has a beta of 2.175, which suggesting that the stock is 117.492% more volatile than S&P 500. In comparison NovaBay Pharmaceuticals, Inc. has a beta of 0.569, suggesting its less volatile than the S&P 500 by 43.103%.

Immunome, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.80 per share. Immunome, Inc. pays -- of its earnings as a dividend. NovaBay Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Immunome, Inc. quarterly revenues are --, which are smaller than NovaBay Pharmaceuticals, Inc. quarterly revenues of $521K. Immunome, Inc.'s net income of -$57.5M is lower than NovaBay Pharmaceuticals, Inc.'s net income of -$1.3M. Notably, Immunome, Inc.'s price-to-earnings ratio is -- while NovaBay Pharmaceuticals, Inc.'s PE ratio is 1.78x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Immunome, Inc. is 158.64x versus 2.06x for NovaBay Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.